SOLA Biosciences Japan Secures 6 Billion Yen Grant to Advance ALS Gene Therapy

SOLA Biosciences Japan GK, a subsidiary of Boston-based SOLA Biosciences Inc., has received a grant of approximately 6 billion yen from the Japan Agency for Medical Research and Development (AMED) to advance its gene therapy program SOL-257 for amyotrophic lateral sclerosis (ALS). The grant, part of AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, will support the development of SOL-257 over […]

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.